Using Sacituzumab Govitecan and Other ADCs in Urothelial Cancers
Arlene O. Siefker-Radtke, MD, discusses the data seen with sacituzumab govitecan, an antibody-drug conjugate that targets TROP-2, which is expressed frequently in urothelial cancer cells.
Arlene O. Siefker-Radtke, MD, professor, department of genitourinary medical oncology, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the data seen with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) that targets TROP-2, which is expressed frequently in urothelial cancer cells.
Response rates were around 30% with this agent, but it was associated with toxicites, says Siefker-Radtke. However, toxicities are common with other ADCs, such as enfortumab vedotin, which has a higher rate of neutropenia and neutropenic fevers.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
